Ann: Imugene PD1-Vaxx Immunotherapy Patent Granted in the US, page-27

IMU ...
received a Notice ofAllowance from the U.S. Patent and Trademark Office (USPTO) for patent applicationnumber 16/498,929, related to its B-cell activating immunotherapy PD1-Vaxx, currently inclinical development for non-small cell lung cancer (NSCLC).

One more critical step taken successfully. Locking up the IP.

It becomes increasing clear that IMU is totally committed to its B-Cell therapies. And why shouldn't it be? IMU is ...
++ a world leader in B-Cell technology
++ seeing amazing results already with ...
- HER-Vaxx (long term survival in late stage cancer patients)
- PD1-Vaxx (long term survival in late stage cancer patients)
++ taking safe treatments into combo with the world's (current) leading cancer treatments ( Tecentiqa, Keytruda, etc)
++ about to enter into a trial for naïve NSCLC patients (ie. not already knocked about by previous 'nasty' treatments)

All good as I see it.
Of course some will find fault with ongoing successes, ie. not fast enough or where's the income?
But with Bio-tech trials it takes time. We are closer than we have ever been. Who knows when that first deal will drop?
Could be sooner than many think.

All opinion of course. Seek professional advice as needed.